Human PD-1 Protein, His tag (Nanoparticle) is designed and expressed as nanoparticles of approximately 25 nm diameter by displaying PD-1 ECD in native conformation. The nanoparticles each was coated with an average of 180 PD-1 ECD.
The nanoparticle technology allows directional and high-density display of human PD-1 on the surface of nanoparticles, thus greatly enhances the immune response in vivo to otherwise poorly immunogenic epitopes.
This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 47.1 kDa. The protein migrates as 55-65 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS with glycine and sodium citrate, pH8.0. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human PD-1, His tag (Nanoparticle) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.
Immobilized Human PD-1, His tag (Nanoparticle) (Cat. No. PD1-H52H2) at 1 μg/mL (100 μL/well) can bind Nivolumab with a linear range of 0.2-2 ng/mL (QC tested).
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
Price(USD) : $950.00
Price(USD) : $3550.00
Price(USD) : $6280.00
Emerging VoCs, Lambda, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ELISA kits for neutralizing antibody titer assay, binding antibody titer assay, antibody isotype assay, antigen titer assay and inhibitor screening, etc., which can accelerate the research and development of anti-SARS-CoV-2 drugs and vaccines.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2， CD133, GPRC5D，CCR8, CCR5, etc.
This web search service is supported by Google Inc.